Drug intelligence / Profile preview

YAQ001

Development stage: Preclinical
Lead developer: Yaqrit
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

YAQ001 (Carbalive) is an orally administered, non-absorbable medical device developed by Yaqrit for the treatment of advanced liver disease, specifically decompensated cirrhosis. It consists of highly engineered, nanoporous carbon beads with a dual pore structure (macroporous and microporous) designed to selectively adsorb and remove lipopolysaccharides (LPS), bacterial toxins, and inflammatory molecules from the gastrointestinal tract. By restricting its action to the gut, YAQ001 modulates the gut microbiome ecosystem, increasing beneficial bacteria while suppressing pathogenic taxa and inhibiting biofilm formation. This approach aims to reduce systemic inflammation and prevent the progression of cirrhosis without killing beneficial bacteria. In Europe, it is classified as a medical device and is also being investigated for irritable bowel syndrome (IBS).

Brand names: Carbalive

Beyond the preview

Go deeper on YAQ001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YAQ001.

Explore the full profile